Європейський Союз - угорська - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - a lófélék immunológiai vizsgálata - lovak - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

Європейський Союз - угорська - EMA (European Medicines Agency)

serb sa - amifampridine foszfát - lambert-eaton myasthenic syndrome; paraneoplastic syndromes, nervous system; nervous system neoplasms; paraneoplastic syndromes; nervous system diseases; autoimmune diseases of the nervous system; neurodegenerative diseases; neuromuscular diseases; neuromuscular junction diseases; immune system diseases; autoimmune diseases; autoimmune diseases of the nervous system; cancer; neoplasms - egyéb idegrendszeri gyógyszerek - lambert-eaton myastheniás szindróma (lems) tüneti kezelése felnőtteknél.

Європейський Союз - угорська - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Угорщина - угорська - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

sandoz hungária kft. - rosuvastatin; ezetimibe -

Угорщина - угорська - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

sandoz hungária kft. - rosuvastatin; ezetimibe -

Угорщина - угорська - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

sandoz hungária kft. - rosuvastatin; ezetimibe -

Угорщина - угорська - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

sandoz hungária kft. - rosuvastatin; ezetimibe -

Угорщина - угорська - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

biodrug s.r.o. - mycobacterium bovis bcg (bacillus calmette-guerin) -

Європейський Союз - угорська - EMA (European Medicines Agency)

sandoz gmbh - natalizumabot - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunszuppresszánsok - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 és 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.